This monograph demonstrates empirically how the free-market system of drug pricing is vital to the development of new breakthrough drugs.

Creating price controls on pharmaceuticals could stifle the development of new breakthrough drugs.

At this event, John A. Vernon and Joseph H. Golec will discuss their new AEI Press book.

This paper identifies two mechanisms through which price regulation (or reimportation) may exert an influence on research and development.

The author examines the effect of existing foreign regulation on U.S. firms, the major producers of innovative drugs.

The trade in inferior quality medicines kills innocent patients. Perhaps 15 percent of the global drug supply outside of advanced countries is counterfeit, rising in certain markets in parts of Africa and Asia to over 50 percent. But counterfeits are not the only low-quality drugs on the market.

Developing new, effective drugs is staggeringly expensive, and the high prices of certain drugs on the market are directly related to this initial investment, according to a new AEI Press book.

The FDA must continue to pressure Chinese authorities to test what is on the market and remove any substandard products found.